Pharsight

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5412095	ABBOTT	Terazosin monohydrochloride and processes and intermediate for its production	Apr, 2013 (11 years ago)
US5294615	ABBOTT	Terazosin polymorph and pharmaceutical composition	Apr, 2013 (11 years ago)

Hytrin is owned by Abbott.

Hytrin contains Terazosin Hydrochloride.

Hytrin has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Hytrin are:

Hytrin was authorised for market use on 07 August, 1987.

Hytrin is available in tablet;oral, capsule;oral dosage forms.

Hytrin can be used as treatment of symptomatic benign prostatic hyperplasia.

The generics of Hytrin are possible to be released after 29 April, 2013.

Market Authorisation Date: 07 August, 1987

Treatment: Treatment of symptomatic benign prostatic hyperplasia

Dosage: TABLET;ORAL; CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg, 2 mg, 5 mg and 10 mg
1 mg, 2 mg, 5 mg and 10 mg

Strength	Dosage	Availability
EQ 1MG BASE	TABLET;ORAL	Discontinued
EQ 2MG BASE	TABLET;ORAL	Discontinued
EQ 1MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
EQ 5MG BASE	TABLET;ORAL	Discontinued
EQ 10MG BASE	TABLET;ORAL	Discontinued
EQ 10MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
EQ 2MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued
EQ 5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued

Hytrin patents expiration